Search

Your search keyword '"Van de Velde, C."' showing total 552 results
Start Over Author "Van de Velde, C." Search Limiters Available in Library Collection
552 results on '"Van de Velde, C."'

3. Effect of preoperative chemotherapy on the histopathological classification of gastric cancer

Author

Caspers, I. A., primary, Biesma, H. D., additional, Wiklund, K., additional, Pontén, F., additional, Lind, P., additional, Nordsmark, M., additional, Sikorska, K., additional, Meershoek-KleinKranenbarg, E., additional, Hartgrink, H. H., additional, van de Velde, C. J. H., additional, van Sandick, J. W., additional, Verheij, M., additional, Cats, A., additional, and van Grieken, N. C. T., additional

Published
2023
Full Text
View/download PDF

5. 89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study

Author

Linders, D. G. J., primary, Deken, M. M., additional, van Dam, M. A., additional, Wasser, M. N. J. M., additional, Voormolen, E. M. C., additional, Kroep, J. R., additional, van Dongen, G. A. M. S., additional, Vugts, D., additional, Oosterkamp, H. M., additional, Straver, M. E., additional, van de Velde, C. J. H., additional, Cohen, D., additional, Dibbets-Schneider, P., additional, van Velden, F. H. P., additional, Pereira Arias-Bouda, L. M., additional, Vahrmeijer, A. L., additional, Liefers, G. J., additional, de Geus-Oei, L. F., additional, and Hilling, D. E., additional

Published
2023
Full Text
View/download PDF

7. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Author

Dijkstra, E. A., Zwart, W. H., Nilsson, P. J., Putter, H., Roodvoets, A. G. H., Kranenbarg, E. Meershoek-Klein, Froedin, J. E., Nygren, Peter, ostergaard, L., Kersten, C., Verbiene, I., Cervantes, A., Hendriks, M. P., Capdevila, J., Edhemovic, I., van de Velde, C. J. H., Marijnen, C. A. M., van Etten, B., Hospers, G. A. P., Glimelius, Bengt, Dijkstra, E. A., Zwart, W. H., Nilsson, P. J., Putter, H., Roodvoets, A. G. H., Kranenbarg, E. Meershoek-Klein, Froedin, J. E., Nygren, Peter, ostergaard, L., Kersten, C., Verbiene, I., Cervantes, A., Hendriks, M. P., Capdevila, J., Edhemovic, I., van de Velde, C. J. H., Marijnen, C. A. M., van Etten, B., Hospers, G. A. P., and Glimelius, Bengt

Abstract

Background: Pre-operative chemoradiotherapy (CRT) rather than radiotherapy (RT) has resulted in fewer locoregional recurrences (LRRs), but no decrease in distant metastasis (DM) rate for patients with locally advanced rectal cancer (LARC). In many countries, patients receive post-operative chemotherapy (pCT) to improve oncological outcomes. We investigated the value of pCT after pre-operative CRT in the RAPIDO trial. Patients and methods: Patients were randomised between experimental (short-course RT, chemotherapy and surgery) and standard-of-care treatment (CRT, surgery and pCT depending on hospital policy). In this substudy, we compared curatively resected patients from the standard-of-care group who received pCT (pCT+ group) with those who did not (pCT- group). Subsequently, patients from the pCT+ group who received at least 75% of the prescribed chemotherapy cycles (pCT >75% group) were compared with patients who did not receive pCT (pCT-/- group). By propensity score stratification (PSS), we adjusted for the following unbalanced confounders: age, clinical extramural vascular invasion, distance to the anal verge, ypT stage, ypN stage, residual tumour, serious adverse event (SAE) and/or readmission within 6 weeks after surgery and SAE related to pre-operative CRT. Cumulative probability of disease-free survival (DFS), DM, LRR and overall survival (OS) was analysed by Cox regression. Results: In total, 396/452 patients had a curative resection. The number of patients in the pCT+, pCT >75%, pCT- and pCT-/- groups was 184, 112, 154 and 149, respectively. The PSS-adjusted analyses for all endpoints demonstrated hazard ratios between approximately 0.7 and 0.8 (pCT+ versus pCT-), and 0.5 and 0.8 (pCT >75% versus pCT-/-). However, all 95% confidence intervals included 1. Conclusions: These data suggest a benefit of pCT after pre-operative CRT for patients with high-risk LARC, with approximately 20%-25% improvement in DFS and OS and 20%-25% risk reductions in DM

Published
2023
Full Text
View/download PDF

8. Authors' reply-A sensitivity analysis of the RAPIDO clinical trial

Author

Dijkstra, E. A., Zwart, W. H., Putter, H., Marijnen, C. A. M., Nilsson, P. J., van de Velde, C. J. H., van Etten, B., Hospers, G. A. P., Glimelius, Bengt, Dijkstra, E. A., Zwart, W. H., Putter, H., Marijnen, C. A. M., Nilsson, P. J., van de Velde, C. J. H., van Etten, B., Hospers, G. A. P., and Glimelius, Bengt

Published
2023
Full Text
View/download PDF

9. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES

Author

Jassem, J., Brociek, A., Pliszka, A., Andersen, J., Bruun Rasmussen, B., van de Velde, C., Meershoek, E., Paridaens, R., Delorge, A., Coates, A., Camler, R., Coombes, R.C., Mousa, K., Reed, S., Verhoeven, D., Herman, S., Visini, M., Lonning, P., Speirs, V., Viale, G., Palmieri, C., Reed, S.N., Nicholas, H., Cheang, M., Lønning, P.E., Kalaitzaki, E., van de Velde, C.J.H., Rasmussen, B.B., Verhoeven, D.M., Shaaban, A.M., Bartlett, J.M.S., and Bliss, J.M.

Published
2015
Full Text
View/download PDF

10. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial

Author

Dijkstra, E A, Zwart, W H, Nilsson, P J, Putter, H, Roodvoets, A G H, Meershoek-Klein Kranenbarg, E, Frödin, J E, Nygren, P, Østergaard, L, Kersten, C, Verbiené, I, Cervantes, A, Hendriks, M P, Capdevila, J, Edhemovic, I, van de Velde, C J H, Marijnen, C A M, van Etten, B, Hospers, G A P, Glimelius, B, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
post-operative chemotherapy, Cancer Research, oncological outcomes, propensity score stratification, Neoadjuvant Therapy/methods, Rectal Neoplasms/drug therapy, Infant, Disease-Free Survival, Chemoradiotherapy/methods, adjuvant chemotherapy, Neoplasm Recurrence, Local/drug therapy, Oncology, locally advanced rectal cancer, Humans
Abstract

BACKGROUND: Pre-operative chemoradiotherapy (CRT) rather than radiotherapy (RT) has resulted in fewer locoregional recurrences (LRRs), but no decrease in distant metastasis (DM) rate for patients with locally advanced rectal cancer (LARC). In many countries, patients receive post-operative chemotherapy (pCT) to improve oncological outcomes. We investigated the value of pCT after pre-operative CRT in the RAPIDO trial.PATIENTS AND METHODS: Patients were randomised between experimental (short-course RT, chemotherapy and surgery) and standard-of-care treatment (CRT, surgery and pCT depending on hospital policy). In this substudy, we compared curatively resected patients from the standard-of-care group who received pCT (pCT+ group) with those who did not (pCT- group). Subsequently, patients from the pCT+ group who received at least 75% of the prescribed chemotherapy cycles (pCT ≥75% group) were compared with patients who did not receive pCT (pCT-/- group). By propensity score stratification (PSS), we adjusted for the following unbalanced confounders: age, clinical extramural vascular invasion, distance to the anal verge, ypT stage, ypN stage, residual tumour, serious adverse event (SAE) and/or readmission within 6 weeks after surgery and SAE related to pre-operative CRT. Cumulative probability of disease-free survival (DFS), DM, LRR and overall survival (OS) was analysed by Cox regression.RESULTS: In total, 396/452 patients had a curative resection. The number of patients in the pCT+, pCT >75%, pCT- and pCT-/- groups was 184, 112, 154 and 149, respectively. The PSS-adjusted analyses for all endpoints demonstrated hazard ratios between approximately 0.7 and 0.8 (pCT+ versus pCT-), and 0.5 and 0.8 (pCT ≥75% versus pCT-/-). However, all 95% confidence intervals included 1.CONCLUSIONS: These data suggest a benefit of pCT after pre-operative CRT for patients with high-risk LARC, with approximately 20%-25% improvement in DFS and OS and 20%-25% risk reductions in DM and LRR. Compliance with pCT additionally reduces or improves all endpoints by 10%-20%. However, differences are not statistically significant.

Published
2023
Full Text
View/download PDF

11. Long-term stoma-related reinterventions after anterior resection for rectal cancer with or without anastomosis: population data from the Dutch snapshot study

Author

Hazen, S. J. A., Vogel, I., Borstlap, W. A. A., Dekker, J. W. T., Tuynman, J. B., Tanis, P. J., Kusters, M., Deijen, C. L., den Dulk, M., Bonjer, H. J., van de Velde, C. J., Aalbers, A. G. J., Acherman, Y., Algie, G. D., von Geusau, B. Alting, Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Burger, J. W. A., Buskens, C. J., de Mik, S. M. L., van Duijvendijk, P., Gooszen, J. A. H., Hoogland, P., Lamme, B., Marres, C. C., Musters, G. D., van Rossem, C. C., Schreuder, A. M., Swank, H. A., van beek, S. C., van Westreenen, H. L., Westerduin, E., Surgery, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, APH - Global Health, APH - Quality of Care, CCA - Cancer biology and immunology, Anatomy and neurosciences, General practice, Obstetrics and gynaecology, VU University medical center, Amsterdam Reproduction & Development (AR&D), Graduate School, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
medicine.medical_specialty, Colorectal cancer, Anastomosis, medicine.medical_treatment, digestive system, Stoma, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], medicine, Rectal cancer, business.industry, Gastroenterology, Colostomy, Permanent stoma, Anterior resection, medicine.disease, digestive system diseases, Colorectal surgery, Surgery, medicine.anatomical_structure, surgical procedures, operative, Sphincter, Hartmann’s procedure, business, Cohort study, Abdominal surgery
Abstract

Item does not contain fulltext BACKGROUND: The aim of this study was to analyze the stoma-related reinterventions, complications and readmissions after an anterior resection for rectal cancer, based on a cross-sectional nationwide cohort study with 3-year follow-up. METHODS: Rectal cancer patients who underwent a resection with either a functional anastomosis, a defunctioned anastomosis, or Hartmann's procedure (HP) with an end colostomy in 2011 in 71 Dutch hospitals were included. The primary outcome was number of stoma-related reinterventions. RESULTS: Of the 2095 patients with rectal cancer, 1400 patients received an anterior resection and were included in this study; 257 received an initially functional anastomosis, 741 a defunctioned anastomosis, and 402 patients a HP. Of the 1400 included patients, 62% were males, 38% were females and the mean age was 67 years (SD 11.1). Following a primary functional anastomosis, 48 (19%) patients received a secondary stoma. Stoma-related complications occurred in six (2%) patients, requiring reintervention in one (0.4%) case. In the defunctioned anastomosis group, stoma-related complications were present in 92 (12%) patients, and required reintervention in 23 (3%) patients, in 10 (1%) of these more than 1 year after initial resection. Stoma-related complications occurred in 92 (23%) patients after a HP, and required reintervention in 39 (10%) patients in 17 (4%) of cases more than 1 year after initial resection. The permanent stoma rate was 11% and 20%, in the functional anastomosis and the defuctioned anastomosis group, respectively. The end colostomy in the HP group was reversed in 4% of cases. CONCLUSIONS: Construction of a stoma after resection for rectal cancer with preservation of the sphincter is accompanied with long-term stoma-related morbidity. Stoma complications are more frequent after a HP. Even after 1 year, a significant number of reinterventions are required.

Published
2022
Full Text
View/download PDF

12. 89 Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study.

Author

Linders, D. G. J., Deken, M. M., van Dam, M. A., Wasser, M. N. J. M., Voormolen, E. M. C., Kroep, J. R., van Dongen, G. A. M. S., Vugts, D., Oosterkamp, H. M., Straver, M. E., van de Velde, C. J. H., Cohen, D., Dibbets-Schneider, P., van Velden, F. H. P., Pereira Arias-Bouda, L. M., Vahrmeijer, A. L., Liefers, G. J., de Geus-Oei, L. F., and Hilling, D. E.

Subjects
BREAST tumor diagnosis, PILOT projects, TRASTUZUMAB, EPIDERMAL growth factor receptors, POSITRON emission tomography computed tomography, LYMPH nodes, TREATMENT effectiveness, DUCTAL carcinoma, BREAST cancer, QUALITATIVE research, CANCER patients, RESEARCH funding, COMBINED modality therapy, BREAST tumors
Abstract

Simple Summary: In breast cancer patients in whom tumor cells overexpress the protein human epidermal growth factor receptor 2 (HER2), HER2-targeted therapy is the mainstay of neoadjuvant therapy (NAT). Two thirds of these patients respond so well to HER2-targeted therapy that during microscopic analysis of the surgically resected tissue, it becomes apparent there are no vital tumor cells left, classified as complete responders. These patients might not have needed surgery. However, with current imaging techniques such as MRI, it remains difficult to preoperatively assess whether there is residual tumor after NAT or not, so all patients still undergo surgery. This study investigated if a HER2-targeted PET/CT scan can reliably assess the response to NAT. In six patients, a HER2-targeted PET/CT scan was acquired before and after NAT. Two out of six patients had residual tumor at microscopic analysis. Visual assessment of the PET/CT scans correctly predicted the response in 66.7% of cases. When the PET/CT signal in both the scan before and after NAT was quantified and (percentual) changes were calculated, there was a difference in the change of signal between patients with and without residual tumor. This difference, although not statistically significant due to the limited patient number in this study, suggests that quantitative assessment of HER2-targeted PET/CT can be used for accurate response evaluation after NAT. Background: Approximately 20% of invasive ductal breast malignancies are human epidermal growth factor receptor 2 (HER2)-positive. These patients receive neoadjuvant systemic therapy (NAT) including HER2-targeting therapies. Up to 65% of patients achieve a pathological complete response (pCR). These patients might not have needed surgery. However, accurate preoperative identification of a pCR remains challenging. A radiologic complete response (rCR) on MRI corresponds to a pCR in only 73% of patients. The current feasibility study investigates if HER2-targeted PET/CT-imaging using Zirconium-89 (89Zr)-radiolabeled trastuzumab can be used for more accurate NAT response evaluation. Methods: HER2-positive breast cancer patients scheduled to undergo NAT and subsequent surgery received a 89Zr-trastuzumab PET/CT both before (PET/CT-1) and after (PET/CT-2) NAT. Qualitative and quantitative response evaluation was performed. Results: Six patients were enrolled. All primary tumors could be identified on PET/CT-1. Four patients had a pCR and two a pathological partial response (pPR) in the primary tumor. Qualitative assessment of PET/CT resulted in an accuracy of 66.7%, compared to 83.3% of the standard-of-care MRI. Quantitative assessment showed a difference between the SUVR on PET/CT-1 and PET/CT-2 (ΔSUVR) in patients with a pPR and pCR of −48% and −90% (p = 0.133), respectively. The difference in tumor-to-blood ratio on PET/CT-1 and PET/CT-2 (ΔTBR) in patients with pPR and pCR was −79% and −94% (p = 0.133), respectively. Three patients had metastatic lymph nodes at diagnosis that were all identified on PET/CT-1. All three patients achieved a nodal pCR. Qualitative assessment of the lymph nodes with PET/CT resulted in an accuracy of 66.7%, compared to 50% of the MRI. Conclusions: NAT response evaluation using 89Zr-trastuzumab PET/CT is feasible. In the current study, qualitative assessment of the PET/CT images is not superior to standard-of-care MRI. Our results suggest that quantitative assessment of 89Zr-trastuzumab PET/CT has potential for a more accurate response evaluation of the primary tumor after NAT in HER2-positive breast cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial

Author

Bartlett, J.M., primary, Xu, K., additional, Wong, J., additional, Pond, G., additional, Zhang, Y., additional, Spears, M., additional, Salunga, R., additional, Mallon, E., additional, Taylor, K.J., additional, Hasenburg, A., additional, Markopoulos, C., additional, Dirix, L.Y., additional, Seynaeve, C., additional, van de Velde, C., additional, Rea, D., additional, Schnabel, C.A., additional, Treuner, K., additional, and Bayani, J., additional

Published
2022
Full Text
View/download PDF

16. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES†

Author

Speirs, V., Viale, G., Mousa, K., Palmieri, C., Reed, S. N., Nicholas, H., Cheang, M., Jassem, J., Lønning, P. E., Kalaitzaki, E., van de Velde, C. J. H., Rasmussen, B. B., Verhoeven, D. M., Shaaban, A. M., Bartlett, J. M. S., Bliss, J. M., Coombes, R. C., Jassem, J., Brociek, A., Pliszka, A., Andersen, J., Bruun Rasmussen, B., van de Velde, C., Meershoek, E., Paridaens, R., Delorge, A., Coates, A., Camler, R., Coombes, R.C., Mousa, K., Reed, S., Verhoeven, D., Herman, S., Visini, M., and Lonning, P.

Published
2015
Full Text
View/download PDF

17. Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial

Author

van Amelsfoort, R. M., Walraven, I., Kieffer, J., Jansen, E. P. M., Cats, A., van Grieken, N. C. T., Meershoek-Klein Kranenbarg, E., Putter, H., van Sandick, J. W., Sikorska, K., van de Velde, C. J. H., Aaronson, N. K., Verheij, M., Boot, H., Trip, A., van Coevorden, F., Vanhoutvin, S., Swellengrebel, H. A. M., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., van Laarhoven, H. W. M., Loosveld, O. J. L., ten Tije, A. J., Erdkamp, F. L. G., Warmerdam, F. A. R. M., van der Peet, D. L., Verheul, H. M. W., Portielje, J. E. A., Spillenaar Bilgen, E. J., Poleé, M. B., Geenen, M. M., Neelis, K. J., Slingerland, M., Jansen, R. L. H., van Spronsen, D. J., Tanis, B. C., van Hillegersberg, R., Koopman, M., den Boer, M. O., Creemers, G. J., van den Berg, H. P., Baars, A., Appels, M. I. E., Smit, J. M., Muller, E. W., de Boer, J., van Dijk, M. A., van der Gaast, A., Otten, J. M. M. B., Ceha, H. M., Radiotherapy, CCA - Cancer Treatment and Quality of Life, Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Oncology, Pathology, Amsterdam Gastroenterology Endocrinology Metabolism, Internal medicine, CCA - Cancer Treatment and quality of life, Medical oncology, and Medical Oncology

Subjects
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Oncology, Stomach Neoplasms, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Surveys and Questionnaires, Quality of Life, Humans, Prognosis, Neoadjuvant Therapy
Abstract

Background: The evaluation of health-related quality of life (HRQoL) in clinical trials has become increasingly important because it addresses the impact of treatment from the patient’s perspective. The primary aim of this study was to investigate the effect of postoperative chemotherapy and chemoradiotherapy (CRT) after neoadjuvant chemotherapy and surgery with extended (D2) lymphadenectomy on HRQoL in the CRITICS trial. Second, we investigated the potential prognostic value of pretreatment HRQoL on event-free survival (EFS) and overall survival (OS). Patients and Methods: Patients in the CRITICS trial were asked to complete HRQoL questionnaires (EORTC Quality-of-Life Questionnaire-Core 30 and Quality-of-Life Questionnaire gastric cancer–specific module) at baseline, after preoperative chemotherapy, after surgery, after postoperative chemotherapy or CRT, and at 12 months follow-up. Patients with at least 1 evaluable questionnaire (645 of 788 randomized patients) were included in the HRQoL analyses. The predefined endpoints included dysphagia, pain, physical functioning, fatigue, and Quality-of-Life Questionnaire-Core 30 summary score. Linear mixed modeling was used to assess differences over time and at each time point. Associations of baseline HRQoL with EFS and OS were investigated using multivariate Cox proportional hazards analyses. Results: At completion of postoperative chemo(radio)therapy, the chemotherapy group had significantly better physical functioning (P=.02; Cohen’s effect size = 0.42) and less dysphagia (P=.01; Cohen’s effect size = 0.38) compared with the CRT group. At baseline, worse social functioning (hazard ratio [HR], 2.20; 95% CI, 1.36–3.55; P=.001), nausea (HR, 1.89; 95% CI, 1.39–2.56; PP=.007), and histologic subtype (diffuse vs intestinal: HR, 1.94; 95% CI, 1.42–2.67; PP=.003) were significantly associated with worse EFS and OS. Conclusions: In the CRITICS trial, the chemotherapy group had significantly better physical functioning and less dysphagia after postoperative treatment. HRQoL scales at baseline were significantly associated with EFS and OS.

Published
2022
Full Text
View/download PDF

18. Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery.

Author

Osong, B, Masciocchi, C, Damiani, A, Bermejo, I, Meldolesi, E, Chiloiro, G, Berbee, M, Lee, SH, Dekker, A, Valentini, V, Gerard, J-P, Rödel, C, Bujko, K, van de Velde, C, Folkesson, J, Sainato, A, Glynne-Jones, R, Ngan, S, Brændengen, M, Sebag-Montefiore, D, van Soest, J, Osong, B, Masciocchi, C, Damiani, A, Bermejo, I, Meldolesi, E, Chiloiro, G, Berbee, M, Lee, SH, Dekker, A, Valentini, V, Gerard, J-P, Rödel, C, Bujko, K, van de Velde, C, Folkesson, J, Sainato, A, Glynne-Jones, R, Ngan, S, Brændengen, M, Sebag-Montefiore, D, and van Soest, J

Abstract

BACKGROUND AND PURPOSE: Tumor recurrence, a characteristic of malignant tumors, is the biggest concern for rectal cancer survivors. The epidemiology of the disease calls for a pressing need to improve healthcare quality and patient outcomes. Prediction models such as Bayesian networks, which can probabilistically reason under uncertainty, could assist caregivers with patient management. However, some concerns are associated with the standard approaches to developing these structures in medicine. Therefore, this study aims to compare Bayesian network structures that stem from these two techniques. PATIENTS AND METHODS: A retrospective analysis was performed on 6754 locally advanced rectal cancer (LARC) patients enrolled in 14 international clinical trials. Local tumor recurrence at 2, 3, and 5-years was defined as the endpoints of interest. Five rectal cancer treating physicians from three countries elicited the expert structure. The algorithmic structure was inferred from the data with the hill-climbing algorithm. Structural performance was assessed with calibration plots and area under the curve values. RESULTS: The area under the curve for the expert structure on the training and validation data was above 0.9 and 0.8, respectively, for all the time points. However, the algorithmic structure had superior predictive performance over the expert structure for all time points of interest. CONCLUSION: We have developed and internally validated a Bayesian networks structure from experts' opinions, which can predict the risk of a LARC patient developing a tumor recurrence at 2, 3, and 5 years. Our result shows that the algorithmic-based structures are more performant and less interpretable than expert-based structures.

Published
2022

20. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Author

Van Cutsem, E., Dicato, M., Arber, N., Berlin, J., Cervantes, A., Ciardiello, F., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Geva, R., Glimelius, B., Jones, R. Glynne, Grothey, A., Gruenberger, T., Haller, D., Haustermans, K., Labianca, R., Lenz, H.J., Minsky, B., Nordlinger, B., Ohtsu, A., Pavlidis, N., Rougier, P., Schmiegel, W., Van de Velde, C., Schmoll, H.J., Sobrero, A., and Tabernero, J.

Published
2010
Full Text
View/download PDF

21. Response

Author

van de Water, Willemien, Kiderlen, Mandy, Bastiaannet, Esther, Westendorp, Rudi G.J., van de Velde, C. J. H., de Craen, Anton j. M., and Liefers, Gerrit-Jan

Published
2014
Full Text
View/download PDF

25. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial†

Author

Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, Å., van den Broek, C. B. M., Fokstuen, T., Gelderblom, H., Kapiteijn, E., Leer, J. W. H., Marijnen, C. A. M., Martijn, H., Meershoek-Klein Kranenbarg, E., Nagtegaal, I. D., Påhlman, L., Punt, C. J. A., Putter, H., Roodvoets, A. G. H., Rutten, H. J. T., Steup, W. H., Glimelius, B., and van de Velde, C. J. H.

Published
2015
Full Text
View/download PDF

26. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Author

Verslype, C., Van Cutsem, E., Dicato, M., Arber, N., Berlin, J.D., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Gruenberger, T., Haller, D., Haustermans, K., Hoff, P., Kerr, D., Labianca, R., Moore, M., Nordlinger, B., Ohtsu, A., Rougier, P., Scheithauer, W., Schmoll, H.-J., Sobrero, A., Tabernero, J., and van de Velde, C.

Published
2009
Full Text
View/download PDF

27. Mucinous phenotype is associated with response to neoadjuvant chemotherapy in microsatellite instable resectable gastric cancer

Author

Biesma, H. D., Soeratram, A. T. T. D., Sikorska, K., Caspers, I. A., van Essen, H. F., Egthuijsen, J. M. P., Mookhoek, A., Hoek, D. M., Vos, W., van Laarhoven, H. W. M., Nordsmark, M., van der Peet, D. L., Warmerdam, F. A. R. M., Geenen, M. M., Loosveld, O. J. L., Portielje, J. E. A., Los, M., Kranenbarg, E. Meershoek-Klein, Hartgrink, H. H., van Sandick, J., van de Velde, C. J. H., Verheij, M., Cats, A., Ylstra, B., van Grieken, N. C. T., Pathology, Internal medicine, Surgery, Amsterdam Gastroenterology Endocrinology Metabolism, Radiation Oncology, and CCA - Cancer biology and immunology

Published
2021

30. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

Author

Charehbili, A., van de Ven, S., Smit, V. T. H. B. M., Meershoek-Klein Kranenbarg, E., Hamdy, N. A. T., Putter, H., Heijns, J. B., van Warmerdam, L. J. C., Kessels, L., Dercksen, M., Pepels, M. J., Maartense, E., van Laarhoven, H. W. M., Vriens, B., Wasser, M. N., van Leeuwen-Stok, A. E., Liefers, G. J., van de Velde, C. J. H., Nortier, J. W. R., and Kroep, J. R.

Published
2014
Full Text
View/download PDF

32. O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium

Author

Slawinski, C., primary, Malcomson, L., additional, Barriuso, J., additional, Guo, H., additional, Harkin, A., additional, Iveson, T., additional, Glynne-Jones, R., additional, Van de Velde, C., additional, and Renehan, A., additional

Published
2021
Full Text
View/download PDF

33. 7P An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer

Author

Liefers, G-J., primary, Noordhoek, I., additional, Zhang, Y., additional, Sgroi, D.C., additional, Putter, H., additional, Treuner, K., additional, Wong, J., additional, Meershoek-Klein Kranenbarg, E., additional, Duijm-De Carpentier, M., additional, van de Velde, C., additional, and Schnabel, C.A., additional

Published
2021
Full Text
View/download PDF

34. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study

Author

Fernandez, L. M., Sao Juliao, G. P., Figueiredo, N. L., Beets, G. L., van der Valk, M. J. M., Bahadoer, R. R., Hilling, D. E., Meershoek-Klein Kranenbarg, E., Roodvoets, A. G. H., Renehan, A. G., van de Velde, C. J. H., Habr-Gama, A., Perez, R. O., Abdelrazeq, A., Asoglu, O., Barroca, R., Beveridge, J., Bhowmick, A., Blower, A., Braun, M., Bujko, K., Carter, P., Carvalho, C., Coco, C., Cunningham, C., D'Hoore, A., Dimofte, G., Ding, P., Duff, S., Dwyer, S. T., Epstein, J., Evans, D., Fulford, P., Gaertner, W., Gerard, J. -P., Gollins, S., Harris, R., Harrison, J., Heat, J., Hill, J., Hobbiss, J., Huertas, E., Huq, Z., Iseas, S., Jakobsen, A., Jones, D., Jones, L., Khan, U., Kushwaha, R., Lees, N., Linn, T. Y., Loganathan, S., Lopez Campos, F., Madoff, R., Mamedli, Z. Z., Martling, A., Matzel, K. E., Melenhorst, J., Mitchell, P., Murad-Regadas, S. M., O'Dwyer, S. T., Pairola, A., Paraoan, M., Pares, O., Peeters, K. C. M. J., Pettit, S. H., Pranesh, N., Rajaganeshan, R., Ravi, S., Rawat, S., Richards, D., Riyad, K., Rossi, G., Rutten, H. J. T., Saeed, M., Salaman, J., Sanchez Loria, F., Van der Sande, M. E., Santiago, I., Selvasekar, C., Siddiqui, K. H., Smart, C., Solkar, M. H., Sun Myint, A., Taylor, B., Telford, K., Scott, N., Vaccaro, C. A., Vailati, B. B., Verberne, C., Vieira, P., Vimalchandran, D., Ward, S., Wilson, M. S., Winter, D. C., Witjes, C., Wolthuis, A. M., Zhang, J., Zhang, Z., Coco C. (ORCID:0000-0002-4713-7093), Fernandez, L. M., Sao Juliao, G. P., Figueiredo, N. L., Beets, G. L., van der Valk, M. J. M., Bahadoer, R. R., Hilling, D. E., Meershoek-Klein Kranenbarg, E., Roodvoets, A. G. H., Renehan, A. G., van de Velde, C. J. H., Habr-Gama, A., Perez, R. O., Abdelrazeq, A., Asoglu, O., Barroca, R., Beveridge, J., Bhowmick, A., Blower, A., Braun, M., Bujko, K., Carter, P., Carvalho, C., Coco, C., Cunningham, C., D'Hoore, A., Dimofte, G., Ding, P., Duff, S., Dwyer, S. T., Epstein, J., Evans, D., Fulford, P., Gaertner, W., Gerard, J. -P., Gollins, S., Harris, R., Harrison, J., Heat, J., Hill, J., Hobbiss, J., Huertas, E., Huq, Z., Iseas, S., Jakobsen, A., Jones, D., Jones, L., Khan, U., Kushwaha, R., Lees, N., Linn, T. Y., Loganathan, S., Lopez Campos, F., Madoff, R., Mamedli, Z. Z., Martling, A., Matzel, K. E., Melenhorst, J., Mitchell, P., Murad-Regadas, S. M., O'Dwyer, S. T., Pairola, A., Paraoan, M., Pares, O., Peeters, K. C. M. J., Pettit, S. H., Pranesh, N., Rajaganeshan, R., Ravi, S., Rawat, S., Richards, D., Riyad, K., Rossi, G., Rutten, H. J. T., Saeed, M., Salaman, J., Sanchez Loria, F., Van der Sande, M. E., Santiago, I., Selvasekar, C., Siddiqui, K. H., Smart, C., Solkar, M. H., Sun Myint, A., Taylor, B., Telford, K., Scott, N., Vaccaro, C. A., Vailati, B. B., Verberne, C., Vieira, P., Vimalchandran, D., Ward, S., Wilson, M. S., Winter, D. C., Witjes, C., Wolthuis, A. M., Zhang, J., Zhang, Z., and Coco C. (ORCID:0000-0002-4713-7093)

Abstract

Background: Watch and wait is a novel management strategy in patients with rectal cancer who have a clinical complete response after neoadjuvant chemoradiotherapy. Surveillance of these patients is generally intensive, because local regrowth (with the potential for salvage) occurs in 25% of patients, and distant metastases occur in 10% of patients. It is unclear for how long these patients should be followed up. To address this issue, we did conditional survival modelling using the International Watch & Wait Database (IWWD), which is a large-scale registry of patients with a clinical complete response after neoadjuvant chemotherapy who have been managed by a watch-and-wait strategy. Methods: We did a retrospective, multicentre registry study using a dataset from the IWWD, which includes data from 47 clinics across 15 countries. We selected patients (aged ≥18 years) with rectal cancer who had a clinical complete response after neoadjuvant chemotherapy, and who were subsequently managed by a watch-and-wait strategy between Nov 25, 1991, and Dec 31, 2015. Patients who had not achieved a clinical complete response or who had undergone any surgical procedure were excluded. The criteria used for defining a clinical complete response and the specific surveillance strategies were at the discretion of each participating centre. We used conditional survival modelling to estimate the probability of patients remaining free of local regrowth or distant metastasis for an additional 2 years after sustaining a clinical complete response or being distant metastasis-free for 1, 3, and 5 years from the date of the decision to commence watch and wait. The primary outcomes were conditional local regrowth-free survival at 3 years, and conditional distant metastasis-free survival at 5 years. Findings: We identified 793 patients in the IWWD with clinical complete response who had been managed by a watch-and-wait strategy. Median follow-up was 55·2 months (IQR 36·0–75·6). The probabilit

Published
2021

36. Impact of endocrine therapy on quality of life in early stage breast cancer patients: prospective patient reported outcomes from the international registry INSPIRE

Author

Esgueva, A., primary, Noordhoek, I., additional, Meershoek-Klein Kranenbarg, E., additional, Siso Raber, C., additional, Mátrai, Z., additional, Zhygulin, A., additional, Irmesj, A., additional, Mavioso, C., additional, Meani, F., additional, González, E., additional, Özdemir, M., additional, Allweis, T., additional, Rogowski, K., additional, Rodrigues dos Santos, C., additional, Mora, H., additional, Ponzone, R., additional, Samorani, D., additional, van de Velde, C., additional, Audisio, R.A., additional, and Rubio, I.T., additional

Published
2021
Full Text
View/download PDF

43. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Author

Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., Nagtegaal, I. D., Beets-Tan, R. G., Arnold, D., Ciardiello, F., Hoff, P., Kerr, D., Köhne, C.H., Labianca, R., Price, T., Scheithauer, W., Sobrero, A., Tabernero, J., Aderka, D., Barroso, S., Bodoky, G., Douillard, J. Y., El Ghazaly, H., Gallardo, J., Garin, A., Glynne-Jones, R., Jordan, K., Meshcheryakov, A., Papamichail, D., Pfeiffer, P., Souglakos, I., Turhal, S., and Cervantes, A.

Published
2012
Full Text
View/download PDF

47. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Author

Van Cutsem, E., Dicato, M., Geva, R., Arber, N., Bang, Y., Benson, A., Cervantes, A., Diaz-Rubio, E., Ducreux, M., Glynne-Jones, R., Grothey, A., Haller, D., Haustermans, K., Kerr, D., Nordlinger, B., Marshall, J., Minsky, B. D., Kang, Y. K., Labianca, R., Lordick, F., Ohtsu, A., Pavlidis, N., Roth, A., Rougier, P., Schmoll, H. J., Sobrero, A., Tabernero, J., Van de Velde, C., and Zalcberg, J.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results